Le Lézard
Classified in: Science and technology
Subjects: Conference, Trade Show, Webcast

AstroNova Updates Upcoming Investor Conference Schedule


AstroNova, Inc. (Nasdaq: ALOT) today announced that Gregory A. Woods, President and Chief Executive Officer of AstroNova, will present at the following investor conferences in January:

The Sidoti January Micro Cap presentation was rescheduled from January 17 due to technical difficulties. You can hear the live webcast and an archived replay of the presentation via the "Events & Presentations" section of the AstroNova investor relations website, investors.astronovainc.com.

Management will host 1x1 meetings at the 26th Annual Needham Growth Conference. You can hear the live webcast and an archived replay of the presentation via the "Events & Presentations" section of the AstroNova investor relations website, investors.astronovainc.com.

About AstroNova

AstroNova (Nasdaq: ALOT), a global leader in data visualization technologies since 1969, designs, manufactures, distributes, and services a broad range of products that acquire, store, analyze, and present data in multiple formats.

The Product Identification segment provides a wide array of digital, end-to-end product marking and identification solutions, including hardware, software, and supplies for OEMs, commercial printers, and brand owners. The Test and Measurement segment provides products designed for airborne printing solutions, avionics, and data acquisition. Our aerospace products include flight deck printing solutions, networking hardware, and specialized aerospace-grade supplies. Our data acquisition systems are used in research and development, flight testing, missile and rocket telemetry production monitoring, power, and maintenance applications.

AstroNova is a member of the Russell Microcap® Index and the LD Micro Index (INDEXNYSEGIS: LDMICRO). Additional information is available by visiting https://astronovainc.com/.


These press releases may also interest you

at 06:20
The Game Within The Game: Lucra Establishes B2B Presence with Blockbuster Dave and Buster's Deal
Today, Lucra (www.lucrasports.com), the leading technology provider of gamification services, announces a new partnership with the largest operator of entertainment centers in the world, Dave & Buster's, to provide customers with a fully immersive...

at 06:08
Corelight Secures $150 Million in Series E Funding Led by Accel, with participation from Cisco Investments and CrowdStrike
Corelight, a leader in open network detection and response (NDR), today announced it has raised $150 million in Series E investment led by its first capital investor, Accel, with additional strategic investment from Cisco Investments and CrowdStrike...

at 06:05
ACI Worldwide, Inc. Reports Financial Results for the Quarter Ended March 31, 2024
ACI Worldwide , a global leader in mission-critical, real-time payments software, announced financial results today for the quarter ended March 31, 2024. "Q1 results exceeded our expectations, and we are increasing the high end of our full year...

at 06:05
Sustainability Regulation Propelling Transformation in Corporate Reporting, According to New Survey by Workiva
The majority (81%) of companies not subject to the European Union's Corporate Sustainability Reporting Directive (CSRD) intend to partially or fully align their sustainability disclosures with its requirements, according to an independent survey...

at 06:05
Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer's Disease
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer's disease (AD) and other neurodegenerative disorders, today announced the dosing...

at 06:05
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) today announced that the FDA has approved a label update for LUPKYNIS. The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established...

More news about Science and technology...


News published on and distributed by: